Proteo Inc./Proteo Biotech AG: Successful Completion of Patient Recruitment for the Phase II Clinical Trial on Elafin in Patients with Esophagus Cancer
Published: Apr 23, 2010
IRVINE, Calif. & KIEL, Germany--(BUSINESS WIRE)--Proteo, Inc. (OTCBB: PTEO; WKN: 925981) and its wholly-owned subsidiary Proteo Biotech AG announced today the successful completion of patient recruitment for the Phase II clinical trial on the intravenously administered study drug Elafin. In this blinded, randomized, controlled Phase II clinical trial the effect of Elafin on the postoperative inflammatory reaction is being investigated in patients undergoing esophagectomy for esophagus carcinoma. The trial is being conducted at 3 German university hospitals - Kiel, TU-Munich and Muenster. Birge Bargmann, CEO of Proteo: "We expect to have preliminary data on the efficacy of our elastase inhibitor in the near future and we are optimistic that the results of the trial will meet our expectations."